Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

February 1, 2027

Conditions
Macular Degeneration Choroidal Neovascularization
Interventions
DRUG

Faricimab Injection [Vabysmo]

A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.

Trial Locations (1)

Unknown

RECRUITING

Department of Ophthalmology, United Chrisitian Hospital, Hong Kong

All Listed Sponsors
lead

Hospital Authority, Hong Kong

OTHER_GOV